| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA671: Mepolizumab for treating severe eosinophilic asthma |
|
Medicine details |
|
| Medicine name | mepolizumab (Nucala®) |
| Formulation | 100 mg solution for injection |
| Reference number | 405 |
| Indication | Add-on treatment for severe refractory eosinophilic asthma in adult patients |
| Company | GlaxoSmithKline |
| BNF chapter | Respiratory system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/10/2015 |
| NICE guidance | |